All Articles

The Fortune 250 retailer's 10% dividend hike reflects strong financials and a strategic navigation of a complex, evolving automotive landscape.

The utility giant is using a complex forward sale to fund massive infrastructure upgrades, balancing immediate market jitters with long-term strategic growth.

Veteran wealth architect Dr. Anna Maria Panasiuk brings her billion-dollar asset protection expertise to the prestigious Forbes Finance Council.

A new US-Taiwan partnership will equip unmanned boats with advanced AI, creating autonomous swarms to bolster the island's asymmetric defense strategy.

New Stable OS 2.0 platform uses a single wire instruction to connect digital assets with local settlement, aiming to fix cross-border payment execution.

As top execs head to the Morgan Stanley Luxury Conference, investors eye ELC's plans for global growth, profit recovery, and navigating a new era of beauty.

The world's leading sports academy installs a revolutionary gel track, using 'super shoe' principles to make athletes faster, fitter, and fresher.

Disconnected tech systems create 'invisible leakage' in psychiatric practices, fueling burnout. A new approach aims to unify the operational chaos.

The 2026 Giants of Multiple Sclerosis® awards celebrate the multidisciplinary teams shaping the future of MS, from research to rehabilitation.

Despite a Q3 net loss from market volatility and one-off costs, the energy firm declared its 51st straight dividend, banking on new acquisitions for growth.

Strong Q1 results driven by Australian operations and a record gas compression backlog, offsetting a cautious North American drilling market.

The medical device maker posts its 14th straight growth quarter, with soaring profits and a strategic focus on the underserved bronchiectasis market.

Chad Eberly's recent award highlights a shift in finance, where holistic support for SMBs is proving to be the new winning formula for growth.

Grupo Nutresa posted a 42% EBITDA surge, but a strong peso and rising financial costs pushed its reported net income into the red. What's behind the numbers?

With a new CEO, a half-billion-dollar war chest, and a novel drug pipeline, Damora Therapeutics is making an aggressive play to redefine blood cancer treatment.

With a novel drug for schizophrenia and deep financial backing, LB Pharmaceuticals is advancing a promising new therapy for complex mental illnesses.

South Jersey Industries offers to buy back $287.5M in notes for just 9 cents on the dollar, forcing a tough choice on bondholders. What's behind the move?

The industrial giant affirms its quarterly payout, a sign of stability for investors as it navigates a costly green transition and recent regulatory hurdles.

With its first patient enrolled and key EU approvals, Inhibikase pushes its PAH drug IKT-001 forward, balancing clinical hope with financial realities.

Andersen Group reports a 15.7% revenue jump, but IPO-related costs mask strong operational performance as the firm pursues aggressive global expansion.